|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||0.6650 - 0.6750|
|52 Week Range||0.6650 - 0.6750|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, Jan. 9, 2018 /PRNewswire/ -- Notice is hereby given that Monteverde & Associates PC has filed a class action lawsuit in the United States District Court Southern District of Texas Houston Division, case no. 4:17-cv-03918, on behalf of stockholders of Repros Therapeutics Inc. ("Repros" or the "Company") (RPRX) who held Repros securities and have been harmed by Repros and its board of directors' (the "Board") for alleged violations of Sections 14(d)(4), 14(e), and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") in connection with the tender offer of Company common stock to be purchased by Allergan plc ("Allergan"). Under the terms of the agreement, Repros stockholders are only anticipated to receive $0.67 per share in cash in exchange for each share of Repros. The complaint alleges that this offer is inadequate and alleges that the Schedule 14D-9 Solicitation/Recommendation Statement (the "Recommendation Statement") provides materially incomplete and misleading information about the Company's financials and the transaction, in violation of Sections 14(d)(4), 14(e), and 20(a) of the Exchange Act.
Repros Therapeutics Inc (NASDAQ:RPRX), a USD$25.52M small-cap, is a healthcare company operating in an industry, which continues to be affected by the sustained economic uncertainty and structural trends, such asRead More...
NEW YORK , Dec. 28, 2017 /PRNewswire/ -- Almost Family, Inc. (AFAM) Lifshitz & Miller announces investigation into possible breaches of fiduciary duties by the board in connection with the proposed sale ...
NEW YORK , Dec. 18, 2017 /PRNewswire/ -- Juan Monteverde , founder and managing partner at Monteverde & Associates PC , a boutique securities firm headquartered at the Empire State Building in New York ...